Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A recent report from the European Commission highlights the increasing importance of payer considerations in demonstrating product value through clinical development programmes.
New studies have affirmed the complexity of genetic changes in solid tumours, but also revealed commonalities in the associated pathways, suggesting that a pathway-oriented perspective could aid cancer drug discovery and therapy.
A recent trial indicates that rasagiline might slow down Parkinson's disease progression, and also highlights challenges for the development of disease-modifying drugs.
High-profile programmes aiming to develop the first disease-modifying drug for Alzheimer's disease have suffered major setbacks recently, but there is still strong support for a range of efforts to transform disease treatment.
Pharma collaborations with academic institutions highlight close bilateral partnerships as an emerging trend in pharmaceutical discovery and translational science.
As funding for translational research becomes increasingly available, attention is turning to how to build networks and career structures that will help investigators in the field to flourish.
Following the high-profile ENHANCE trial, in which addition of the cardiovascular drug ezetimibe to statin therapy did not result in additional improvement in an imaging-based measure of atherosclerosis, what are the implications for such studies in the future?
As Novo Nordisk joins Pfizer in abandoning an inhaled insulin product, what are the implications for the future of targeting the lung for delivering protein therapeutics?